Art

Reichweite

Bereiche

Status

Start

Ende

Finanzierungsart

Schlagwörter (Tags)

Kurzbeschreibung/Zielsetzung

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase
3 Study to Assess the Efficacy and Safety of Filgotinib Administered
for 24 weeks in Combination with Conventional Synthetic
Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects
with Moderately to Severely Active Rheumatoid Arthritis Who Have
an Inadequate Response to Biologic DMARD(s) Treatment